DOAC-Stop™ is now offered for simplifying diagnostic problems associated with DOACs. DOACs are known to interfere with almost all clotting tests to varying degrees and sometimes patients who need to be tested for underlying coagulation defects may also be on DOACs. Specific antidotes for individual DOACs are being developed for therapeutic use but are not yet widely available for laboratory use.

DOAC-Stop™ is first of its kind to extract all types of new Direct Oral Anti-Coagulant (DOACs) including dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban and also argatroban from test plasmas with minimal effect on plasma proteins involved in the clotting mechanism. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 10 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants.

Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. We guarantee a competitive price for our reagents.

Main Features: Eliminates all DOAC types from test plasma Has no effect on Heparin, Lupus anticoagulants, Warfarin, or Clotting factors Storage at room temperature Shelf life of 3 years